OTCM
LMMY
Oct 08, Last price
0.02USD
1D
6.43%
IPO
-92.05%
Name
LAMY
Chart & performance
P/E
—
P/S
—
EPS
0.00
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
4k
-67.39%
Net income
51k
P
CFO
-5k
L-88.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Legal address
c/o Business Filings Incorporated, 2232 Dell Range Blvd Ste 200
Cheyenne, WY 82009
US
Cheyenne, WY 82009
US
Headquarters
Bardsley Lane; 10 Sextons House
London, LND SE10 9RQ
GB
London, LND SE10 9RQ
GB
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑05 | 2024‑05 | 2023‑05 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |